{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T05:08:53Z","timestamp":1778389733513,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.contraception.2025.110972","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:58:17Z","timestamp":1748001497000},"page":"110972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A systematic comparison of implementation strategies at three U.S. clinic settings that expanded access to self-administered injectable contraception"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-5709","authenticated-orcid":false,"given":"Jennifer","family":"Karlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Rafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise D.","family":"Berlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.contraception.2025.110972_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.15585\/mmwr.mm7020a2","article-title":"Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate","volume":"70","author":"Curtis","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2025.110972_bib2","series-title":"WHO Consolidated Guideline on self-care interventions for health: sexual and reproductive health and rights","author":"World Health Organization","year":"2019"},{"issue":"2","key":"10.1016\/j.contraception.2025.110972_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001350","article-title":"Self-administration of injectable contraception: a systematic review and meta-analysis","volume":"4","author":"Kennedy","year":"2019","journal-title":"BMJ Glob Health"},{"issue":"5","key":"10.1016\/j.contraception.2025.110972_bib4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jadohealth.2020.03.038","article-title":"Young women\u2019s experiences with subcutaneous depot medroxyprogesterone acetate: a secondary analysis of a one-year randomized trial in Malawi","volume":"67","author":"Burke","year":"2020","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.contraception.2025.110972_bib5","unstructured":"U.S. Food and Drug Administration. Drug Approval Package: Depo-SubQ Provera 104 (Medroxyprogesterone Acetate) NDA #021584. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021584s000_depo-subQTOC.cfm#:\u223c:text=Approval Date%3A\u00a010%2F18%2F2004."},{"key":"10.1016\/j.contraception.2025.110972_bib6","unstructured":"Bodie A. Off-label use of prescription drugs. Congressional Research Service; 2021. Report No. R45792. Available from: https:\/\/sgp.fas.org\/crs\/misc\/R45792.pdf. (accessed March 8, 2023)."},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/AOG.0000000000004524","article-title":"The role of subcutaneous depot medroxyprogesterone acetate in equitable contraceptive care","volume":"138","author":"Burlando","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.contraception.2016.06.006","article-title":"Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States","volume":"94","author":"Upadhyay","year":"2016","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2025.110972_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.AOG.0000459866.14114.33","article-title":"Committee Opinion No. 615","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.110972_bib10","unstructured":"Ensuring Access to Equitable, Affordable, Client-Centered, Quality Family Planning Services. A rule by the Health and Human Services Department on 10\/07\/2021. 2021\u201321542 (86 FR 56144). Available from: \u3008https:\/\/go.usa.gov\/xMfQy\u3009. (accessed October 14, 2024)."},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2025.110972_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106664","article-title":"COVID-19 and family planning service delivery: findings from a survey of U.S. physicians","volume":"150","author":"Zapata","year":"2021","journal-title":"Prev Med"},{"issue":"1","key":"10.1016\/j.contraception.2025.110972_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12978-022-01388-9","article-title":"Assessing differences in contraceptive provision through telemedicine among reproductive health providers during the COVID-19 pandemic in the United States","volume":"19","author":"Comfort","year":"2022","journal-title":"Reprod Health"},{"key":"10.1016\/j.contraception.2025.110972_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2022.03.023","article-title":"Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC)","volume":"112","author":"Kohn","year":"2022","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2025.110972_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.contraception.2020.09.001","article-title":"An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)","volume":"102","author":"Katz","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110972_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.contraception.2022.01.015","article-title":"Would you be interested in DMPA-SC? An implementation project in two urban primary care clinics","volume":"112","author":"Miles","year":"2022","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.contraception.2025.110972_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamapediatrics.2020.1884","article-title":"Providing contraception for young people during a pandemic is essential health care","volume":"174","author":"Wilkinson","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.contraception.2025.110972_bib18","article-title":"Provision of DMPA-SC for self-administration in different practice settings during the COVID-19 pandemic: data from providers across the United States","volume":"131","author":"Comfort","year":"2023","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110972_bib19","unstructured":"Clinical Training Center for Sexual and Reproductive Health (CTC-SRH). A toolkit for user administration of subcutaneous depot medroxyprogesterone acetate. Available from: \u3008https:\/\/ctcsrh.org\/ctcsrh-resource\/user-administration-of-subcutaneous-depot-medroxyprogesterone-acetate-dmpa-sc\/\u3009. (accessed January 13, 2024)."},{"key":"10.1016\/j.contraception.2025.110972_bib20","unstructured":"National Family Planning and Reproductive Health Association. DMPA-SQ Clinical Protocol and Template. Available from: \u3008https:\/\/www.nationalfamilyplanning.org\/file\/NFPRHA---DMPA-SQ-Cinical-Protocol_FINAL-Nov-2020.docx\u3009. (accessed December 23, 2022)."},{"key":"10.1016\/j.contraception.2025.110972_bib21","unstructured":"National Family Planning and Reproductive Health Association. Self-Administration of Injectable Contraception. Available from: \u3008https:\/\/www.nationalfamilyplanning.org\/file\/documents---service-delivery-tools\/NFPRHA---Depo-SQ-Resource-guide---FINAL-FOR-DISTRIBUTION.pdf\u3009. (accessed January 13, 2024)."},{"issue":"1","key":"10.1016\/j.contraception.2025.110972_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","article-title":"A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project","volume":"10","author":"Powell","year":"2015","journal-title":"Implement Sci"},{"key":"10.1016\/j.contraception.2025.110972_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1748-5908-8-139","article-title":"Implementation strategies: recommendations for specifying and reporting","volume":"8","author":"Proctor","year":"2013","journal-title":"Implement Sci"},{"key":"10.1016\/j.contraception.2025.110972_bib24","unstructured":"Lewin ME, Altman S, editors. America\u2019s health care safety net: intact but endangered Institute of Medicine Committee on the changing market, managed care, and the future viability of safety net providers. Washington, DC: National Academies Press; 2000."},{"key":"10.1016\/j.contraception.2025.110972_bib25","unstructured":"Cooper J. Section 1135 Flexibilities Requested in March 16, 2020 and March 19, 2020 Communications. Available from: \u3008https:\/\/www.dhcs.ca.gov\/Documents\/COVID-19\/CA-1135-Flexibilities-Approval-Letter-Rev-032320.pdf\u3009. (accessed May 22, 2020)."},{"key":"10.1016\/j.contraception.2025.110972_bib26","unstructured":"Information Regarding the Use of Subcutaneous Depot Medroxyprogesterone Acetate During the 2019 Novel Coronavirus Public Health Emergency. Available from: \u3008https:\/\/www.dhcs.ca.gov\/Documents\/COVID-19\/Medi-Cal-FFS-Depo-Provera-SQ-Temp-Policy.pdf\u3009. (accessed May 22, 2020)."},{"key":"10.1016\/j.contraception.2025.110972_bib27","unstructured":"Birth Control Pharmacist. Pharmacy-based contraception care during COVID-19. Available from: \u3008https:\/\/birthcontrolpharmacist.com\/training\/careduringcovid\/\u3009. (accessed January 24, 2024)."},{"key":"10.1016\/j.contraception.2025.110972_bib28","unstructured":"Innovating Education. This is how I teach: self-injection DMPA-SC. Available from: \u3008https:\/\/www.innovating-education.org\/2020\/06\/this-is-how-i-teach-self-injection-dmpa-sc\/\u3009. (accessed December 22, 2022)."},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/psrh.12278","article-title":"Patient experiences switching from in\u2010clinic to self\u2010administration of injectable contraception in two Western U.S. states","volume":"56","author":"Newmark","year":"2024","journal-title":"Perspect Sex Reprod Health"},{"issue":"11","key":"10.1016\/j.contraception.2025.110972_bib30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2004.11.013","article-title":"Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg\/0.65 mL) contraceptive formulation in Asian women","volume":"26","author":"Toh","year":"2004","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.contraception.2025.110972_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.contraception.2013.07.002","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","volume":"89","author":"Halpern","year":"2013","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.contraception.2009.03.023","article-title":"When can a woman have repeat progestogen-only injectables\u2013depot medroxyprogesterone acetate or norethisterone enantate?","volume":"80","author":"Paulen","year":"2009","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2025.110972_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera\u00ae","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110972_bib34","unstructured":"Reproductive Health Access Project. Expanding access to the self-administered contraceptive injection. Available from: \u3008https:\/\/www.reproductiveaccess.org\/2020\/07\/contraceptive-injection\/\u3009. (accessed December 23, 2022)."},{"key":"10.1016\/j.contraception.2025.110972_bib35","unstructured":"Nationwide Children\u2019s. Helping hand. Available from: \u3008https:\/\/www.nationwidechildrens.org\/-\/media\/nch\/family-resources\/helping-hands\/documents\/hhiv217.ashx\u3009. (accessed March 14, 2023)."},{"issue":"6","key":"10.1016\/j.contraception.2025.110972_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jpag.2023.06.005","article-title":"A pilot study of adolescent and young adult experience with subcutaneous depot medroxyprogesterone acetate","volume":"36","author":"Wernick","year":"2023","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"5","key":"10.1016\/j.contraception.2025.110972_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1363459320969775","article-title":"This is what the truth is: provider-patient interactions serving as barriers to contraception","volume":"25","author":"Berndt","year":"2020","journal-title":"Health"},{"issue":"2","key":"10.1016\/j.contraception.2025.110972_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/00221465211003232","article-title":"We\u2019re a little biased: medicine and the management of bias through the case of contraception","volume":"62","author":"Manzer","year":"2021","journal-title":"J Health Soc Behav"},{"issue":"4","key":"10.1016\/j.contraception.2025.110972_bib39","doi-asserted-by":"crossref","first-page":"319.e1","DOI":"10.1016\/j.ajog.2010.05.009","article-title":"Recommendations for intrauterine contraception: a randomized trial of the effects of patients\u2019 race\/ethnicity and socioeconomic status","volume":"203","author":"Dehlendorf","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.contraception.2025.110972_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajog.2009.08.022","article-title":"Disparities in family planning","volume":"202","author":"Dehlendorf","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.110972_bib41","unstructured":"Birth Control Pharmacist. Available from: \u3008https:\/\/birthcontrolpharmacist.com\/policies\/\u3009. (accessed March 7, 2023)."},{"key":"10.1016\/j.contraception.2025.110972_bib42","unstructured":"Patient Protection and Affordable Care Act. Public Law. Vol. 111; pp. 119\u201321. Available from: \u3008https:\/\/www.congress.gov\/111\/plaws\/publ148\/PLAW-111publ148.pdf\u3009."},{"key":"10.1016\/j.contraception.2025.110972_bib43","unstructured":"Women\u2019s Preventative Services Initiative (WPSI). Contraception. Available from: \u3008https:\/\/www.womenspreventivehealth.org\/recommendations\/contraception\/\u3009. (accessed October 14, 2024)."},{"issue":"7","key":"10.1016\/j.contraception.2025.110972_bib44","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1089\/jwh.2021.0361","article-title":"Review of publicly available state policies for long-acting reversible contraception device reimbursement","volume":"31","author":"Romero","year":"2022","journal-title":"J Womens Health"},{"issue":"50","key":"10.1016\/j.contraception.2025.110972_bib45","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.15585\/mmwr.mm6650a4","article-title":"Update: providing quality family planning services\u2014recommendations from CDC and the U.S. office of population affairs, 2017","volume":"66","author":"Gavin","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.contraception.2025.110972_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7303a1","article-title":"U.S. selected practice recommendations for contraceptive use, 2024","volume":"73","author":"Curtis","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2025.110972_bib47","unstructured":"Guttmacher Institute. Minors\u2019 access to contraceptive services. State Laws and Policies As of August 30, 2023. Available from: \u3008https:\/\/www.guttmacher.org\/state-policy\/explore\/minors-access-contraceptive-services\u3009. (accessed November 4, 2024)."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425001635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425001635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:13:44Z","timestamp":1778386424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782425001635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"alternative-id":["S0010782425001635"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110972","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic comparison of implementation strategies at three U.S. clinic settings that expanded access to self-administered injectable contraception","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110972"}}